PharmaCell B.V. appoints new CEO
PharmaCell B.V. has appointed Mr. Alexander Vos as Chief Executive Officer, effective November 1st 2009. Mr. Vos has 20 years of leadership experience in the pharma and biotech industry. He joins from PAION AG, where he was a Member of the Management Board (“Vorstand”) and Chief Operating Officer from 2004 onwards.
Mr. Vos started his career at McKinsey & Co. as a strategy consultant in their international pharmaceutical practice. Subsequently, at Genzyme Therapeutics Europe he held executive positions as European Marketing Director and Director of Business Development, before assuming global responsibility for its joint venture with Pharming N.V. From 2000 to 2004, Mr. Vos served as Chief Executive Officer of MediService AG (Switzerland), a specialty pharmacy service companies in Europe, which was successfully sold to Galenica AG. Mr. Vos holds a M.Sc. in Pharmacy and Pharmacology from the University of Amsterdam and an MBA from the Stanford Graduate School of Business.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
NascaCell announces an aptamer distribution agreement in Japan with GE Healthcare
XOMA Announces Planned Retirement of Chief Executive Officer
East German physicians prescribe significantly more high-priced biopharmaceutical medication than West German doctors - 127% higher revenues of pharmaceutical companies per physician and year in the area of former East Germany
Apeiron announces start of phase I trail with cellular anti cancer therapy
Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Acacia Pharma starts clinical trial with APD515 for Xerostomia

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
